BUSINESS
    Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
    By Kohei Hori July 26, 2024
    Takeda Pharmaceutical expects its domestic revenues to start expanding again from FY2025 with a total of four new product releases planned during this fiscal year through March, said Asuka Miyabashira, new president of the company’s…

    LATEST

    Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
    July 26, 2024
    Chugai Pharmaceutical saw its profits rise by double-digits in the first half of 2024 driven by favorable exports to its parent company Roche. Meanwhile, its sales declined mostly due to the end of Ronapreve (casirivimab…
    Merck, GTRI Tie Up in Development of Parkinson’s Gene Therapy
    July 26, 2024
    German Merck’s Japanese subsidiary and the Japanese biotech Gene Therapy Research Institute (GTRI) have agreed to forge a partnership in the process development and manufacturing of a gene therapy for Parkinson’s disease.The collaboration is based…
    Intage, Niigata University Tie Up on Megalin Antagonist Development
    July 26, 2024
    Intage Healthcare and Niigata University said on July 25 that they have launched collaborative research for the AI-powered development of antagonists targeting megalin, which is involved in the onset of acute kidney injury.In this research, Intage will use the three-dimensional…

    COLUMN

    3 Common Mistakes Made when Hiring a Leader
    By Philip Carrigan

    Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…

    COMMENTARY

    Lively Debate on Generic Industry Revamp Underway, All Eyes on Consortium Model
    By Takashi Ebisawa

    Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…

    MHLW Panel on Generic Industry Structure

    MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report

    A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

    MHLW Panel on Pharmaceutical Regulations

    Japan Set to Push Central IRBs for Clinical Trials, Avoid Customary All-Case PMS

    A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

    Drug Approval & Reimbursement in 2023

    Japan Approves Label Expansions for Rexulti, Rituxan, and More

    The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    MHLW Expert Panel on Comprehensive Policies

    Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
    By Yoshinori Sagehashi

    The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

    Chuikyo on Off-Year Drug Price Revision

    Healthcare Providers Rap Product Coverage of Off-Year Re-Pricing, Payers Hail Threshold: Chuikyo

    A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

    Jiho Survey: FY2022 Drug Price Revision

    Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally

    Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

    FY2022 Drug Pricing Reform

    MHLW Unveils New List Prices for FY2022 Revision, 18 Off-Patent APIs Face Early “G1” Cuts

    Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA